complex in cystic fibrosis: critical gaps in diagnosis and therapy.

Juan Carlos Guti��rrez Santana, Victor Rafael Coria Jim��nez
Author Information
  1. Juan Carlos Guti��rrez Santana: Laboratory of Experimental Bacteriology, National Institute of Pediatrics, Mexico City, Mexico. ORCID
  2. Victor Rafael Coria Jim��nez: Laboratory of Experimental Bacteriology, National Institute of Pediatrics, Mexico City, Mexico. ORCID

Abstract

complex () is a bacterial group with 'natural' multi-antimicrobial resistance. This complex has generated epidemic outbreaks across the world. In people with cystic fibrosis (CF), can cause severe lung infections that lead to accelerated lung damage, which can be complicated by necrotizing pneumonia accompanied by high fevers, leucocytosis, and bacteraemia, which commonly causes fatal outcomes. Specifically, infection by is considered an exclusion criterion for lung transplantation. The species of exhibit both genetic and phenotypic hypervariability that complicate their accurate microbiological identification. Automated methods such as MALDI-TOF can err in the determination of species. Their slow growth even in selective agars and the absence of international consensuses on the optimal conditions for their isolation make early diagnosis a difficult challenge to overcome. The absence of correlations between antibiograms and clinical results has resulted in the absence of standardized cut-off values of antimicrobial susceptibility, a fact that brings a latent risk since incorrect antibiotic therapy can induce the selection of more aggressive variants that worsen the clinical picture of the host, added to the absence of a clear therapeutic guide for the eradication of pulmonary infections by in patients with CF, resulting in frequently ineffective treatments. There is an urgent need to standardize methods and diagnostic tools that would allow an early and accurate diagnosis, as well as to perform clinical studies of the effectiveness of available antibiotics to eradicate infections, which would allow us to establish standardized therapeutic schemes for -infected patients.

Keywords

References

  1. Pathogens. 2014 Aug 18;3(3):680-703 [PMID: 25438018]
  2. Antimicrob Resist Infect Control. 2021 Oct 10;10(1):143 [PMID: 34629114]
  3. Emerg Infect Dis. 2020 Sep;26(9):1987-1997 [PMID: 32818396]
  4. Pediatr Infect Dis J. 2020 Oct;39(10):899-906 [PMID: 32453200]
  5. Bol Med Hosp Infant Mex. 2021;78(6):584-596 [PMID: 34934215]
  6. Front Public Health. 2014 Sep 16;2:145 [PMID: 25279369]
  7. FEMS Microbiol Lett. 2008 Apr;281(2):175-82 [PMID: 18312571]
  8. Ann Clin Microbiol Antimicrob. 2019 Feb 4;18(1):7 [PMID: 30717798]
  9. Cochrane Database Syst Rev. 2019 Apr 18;4:CD009876 [PMID: 30997925]
  10. Drug Resist Updat. 2016 Sep;28:82-90 [PMID: 27620956]
  11. Cell. 2020 Apr 2;181(1):29-45 [PMID: 32197064]
  12. Microbiology (Reading). 2023 Aug;169(8): [PMID: 37526960]
  13. Nat Commun. 2019 Jul 30;10(1):3397 [PMID: 31363089]
  14. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  15. Front Pediatr. 2023 May 15;11:1115877 [PMID: 37255574]
  16. Semin Respir Crit Care Med. 2019 Dec;40(6):727-736 [PMID: 31887768]
  17. New Microbiol. 2015 Apr;38(2):281-8 [PMID: 25938755]
  18. Euro Surveill. 2018 Oct;23(42): [PMID: 30352639]
  19. Infect Drug Resist. 2021 Dec 21;14:5575-5593 [PMID: 34992385]
  20. Cureus. 2020 May 16;12(5):e8158 [PMID: 32550075]
  21. Infect Dis Ther. 2022 Aug;11(4):1505-1519 [PMID: 35612693]
  22. Cochrane Database Syst Rev. 2021 Dec 10;12:CD013079 [PMID: 34889457]
  23. Epidemiol Infect. 2022 Aug 04;150:e154 [PMID: 35923078]
  24. Am J Infect Control. 2022 Nov;50(11):1253-1257 [PMID: 35158013]
  25. Eur J Pediatr. 2021 Sep;180(9):2731-2739 [PMID: 34213646]
  26. Vaccines (Basel). 2023 May 30;11(6): [PMID: 37376428]
  27. Pediatr Rev. 2021 Feb;42(2):55-67 [PMID: 33526571]
  28. Transpl Infect Dis. 2023 Apr;25(2):e14041 [PMID: 36864824]
  29. Pathology. 2020 Apr;52(3):366-369 [PMID: 32113671]
  30. J Infect. 2018 Sep;77(3):166-170 [PMID: 30012345]
  31. J Pediatric Infect Dis Soc. 2022 Sep 7;11(Supplement_2):S53-S61 [PMID: 36069899]
  32. Vaccines (Basel). 2021 Jun 18;9(6): [PMID: 34207253]
  33. Cochrane Database Syst Rev. 2019 Jun 13;6:CD013079 [PMID: 31194880]
  34. Exp Ther Med. 2019 Mar;17(3):1870-1876 [PMID: 30783462]
  35. Adv Appl Microbiol. 2019;107:113-140 [PMID: 31128746]
  36. Infect Prev Pract. 2020 Aug 13;2(3):100082 [PMID: 34368718]
  37. J Cyst Fibros. 2022 May;21(3):456-462 [PMID: 35125294]
  38. Metabolomics. 2021 Jan 4;17(1):4 [PMID: 33394183]
  39. Access Microbiol. 2022 Oct 7;4(10):acmi000413 [PMID: 36415733]
  40. Lancet. 2021 Jun 5;397(10290):2195-2211 [PMID: 34090606]
  41. ACS Infect Dis. 2020 May 8;6(5):1154-1168 [PMID: 32212725]
  42. Expert Rev Respir Med. 2016 Jun;10(6):685-97 [PMID: 27175979]
  43. Ann Am Thorac Soc. 2020 Dec;17(12):1542-1548 [PMID: 32678679]
  44. Arch Med Res. 2021 May;52(4):357-361 [PMID: 33309309]
  45. Microorganisms. 2023 Jan 06;11(1): [PMID: 36677442]
  46. Diagn Microbiol Infect Dis. 2013 Oct;77(2):126-8 [PMID: 23891221]
  47. Antibiotics (Basel). 2022 May 06;11(5): [PMID: 35625273]
  48. Turk J Pediatr. 2021;63(2):218-222 [PMID: 33929111]
  49. Eur Respir J. 2005 Aug;26(2):305-8 [PMID: 16055880]
  50. Pediatr Pulmonol. 2023 May;58(5):1337-1343 [PMID: 36815622]
  51. Open Forum Infect Dis. 2022 Mar 09;9(5):ofac114 [PMID: 35434175]
  52. ERJ Open Res. 2023 Jun 26;9(3): [PMID: 37377654]
  53. Antimicrob Agents Chemother. 2018 Aug 27;62(9): [PMID: 29914964]
  54. Arch Razi Inst. 2022 Apr 30;77(2):717-725 [PMID: 36284953]
  55. Children (Basel). 2022 Sep 01;9(9): [PMID: 36138639]
  56. Future Microbiol. 2010 Nov;5(11):1663-74 [PMID: 21133688]
  57. Viruses. 2021 Jul 09;13(7): [PMID: 34372537]
  58. Genes Dis. 2019 Apr 17;6(2):109-119 [PMID: 31194018]
  59. Antimicrob Resist Infect Control. 2018 Nov 19;7:138 [PMID: 30479751]
  60. Microorganisms. 2021 Dec 16;9(12): [PMID: 34946206]
  61. J Family Med Prim Care. 2020 Mar 26;9(3):1407-1412 [PMID: 32509624]

MeSH Term

Humans
Cystic Fibrosis
Burkholderia cepacia complex
Lung Transplantation
Anti-Bacterial Agents
Bacteremia

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0complexcanabsencediagnosiscysticlunginfectionsearlyclinicalfibrosisCFspeciesaccuratemethodsstandardizedantimicrobialtherapytherapeuticpatientsallowbacterialgroup'natural'multi-antimicrobialresistancegeneratedepidemicoutbreaksacrossworldpeoplecausesevereleadaccelerateddamagecomplicatednecrotizingpneumoniaaccompaniedhighfeversleucocytosisbacteraemiacommonlycausesfataloutcomesSpecificallyinfectionconsideredexclusioncriteriontransplantationexhibitgeneticphenotypichypervariabilitycomplicatemicrobiologicalidentificationAutomatedMALDI-TOFerrdeterminationslowgrowthevenselectiveagarsinternationalconsensusesoptimalconditionsisolationmakedifficultchallengeovercomecorrelationsantibiogramsresultsresultedcut-offvaluessusceptibilityfactbringslatentrisksinceincorrectantibioticinduceselectionaggressivevariantsworsenpicturehostaddedclearguideeradicationpulmonaryresultingfrequentlyineffectivetreatmentsurgentneedstandardizediagnostictoolswellperformstudieseffectivenessavailableantibioticseradicateusestablishschemes-infectedfibrosis:criticalgapsBurkholderiacepaciaantibacterialagentsstewardship

Similar Articles

Cited By